ArticleAbdominal radiology (New York)2026
Quantitative MR biomarkers in identifying steatohepatitis and fibrosis associated with metabolic dysfunction associated liver disease-a single center cross-sectional study.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver biopsy is the gold standard for diagnosing metabolic dysfunction associated steatohepatitis (MASH). There is an unmet need for non-invasive tests to differentiate uncomplicated hepatic steatosis from steatohepatitis and fibrotic MASH.
objectivesWe aimed to evaluate the role of T1 relaxation time, MRI-PDFF (Proton density fat fraction), and IVIM (Intravoxel Incoherent motion) in detecting and differentiating MASH from non-MASH group of patients and fibrotic MASH from low-risk/absent MASH group. MATERIAL &
methodsWe prospectively conducted a cross-sectional study of 64 patients with Metabolic dysfunction associated steatotic liver disease (MASLD) and reviewed MRI data from 46 patients who underwent liver biopsy. Dedicated sequences were performed using a 1.5 T MR scanner to derive liver MRI-PDFF, T1, and IVIM values (D-True diffusion coefficient, D*- pseudo diffusion coefficient, and f - perfusion fraction). The NASH CRN (Clinical Research Network) scoring system was used to categorize patients based on biopsy results. MR-derived data were compared with the biopsy results.
resultsMedian T1 values were significantly higher in patients with MASH than the non-MASH group (884.97 ms versus 698.59 ms; p = 0.0002, AUROC (95% CI) 0.828 (0.709-0.947)) and in fibrotic MASH versus low-risk/absent MASH group (870.48 ms versus 695.10 ms; p < 0.0001, AUROC (95% CI) 0.851 (0.742-0.961)). Median MRI-PDFF values were significantly higher in MASH patients compared to non-MASH patients (19.38% vs. 9.46%, p = 0.0004, AUROC (95% CI) 0.808 (0.657-0.937)) and in fibrotic MASH compared to low-risk/absent MASH (20.45% vs. 8.58%, p = 0.0001, AUROC (95% CI) 0.847 (0.730-0.963)). MASH patients showed significantly lower D* (p = 0.0167) and f (p = 0.0382) than the non-MASH group; fibrotic MASH patients had lower D (p = 0.042) and D* (p = 0.025) than the low-risk/absent MASH group. MRI T1 mapping and MRI-PDFF demonstrate good diagnostic accuracy for detecting biopsy-defined MASH and fibrotic MASH. Further large-scale, multicenter studies are required to establish their role in clinical practice and potentially help reduce reliance on liver biopsy.
Indexed as
Identifiers
42429971What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.